United Therapeutics Has Limited Downside Below $95 Level, Credit Suisse Says In Upgrade

By: via Benzinga
Despite shares of United Therapeutics Corporation (NASDAQ: UTHR) being a consistent sell-side short amid mounting risks, a Credit ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.